2291 related articles for article (PubMed ID: 28898379)
1. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
2. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
Giuliano AE; Hunt KK; Ballman KV; Beitsch PD; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; McCall LM; Morrow M
JAMA; 2011 Feb; 305(6):569-75. PubMed ID: 21304082
[TBL] [Abstract][Full Text] [Related]
3. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
[TBL] [Abstract][Full Text] [Related]
4. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.
Giuliano AE; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Hunt KK; Morrow M; Ballman K
Ann Surg; 2010 Sep; 252(3):426-32; discussion 432-3. PubMed ID: 20739842
[TBL] [Abstract][Full Text] [Related]
5. Survival analysis of early-stage breast cancer patients undergoing axillary lymph node dissection and sentinel lymph node dissection.
Nayyar A; Strassle PD; Shen MR; Black JA; Gallagher KK; McGuire KP
Am J Surg; 2018 Oct; 216(4):706-712. PubMed ID: 30060915
[TBL] [Abstract][Full Text] [Related]
6. Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACOSOG Z0011 trial.
Tseng J; Alban RF; Siegel E; Chung A; Giuliano AE; Amersi FF
Breast J; 2021 Mar; 27(3):216-221. PubMed ID: 33586201
[TBL] [Abstract][Full Text] [Related]
7. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
8. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
[TBL] [Abstract][Full Text] [Related]
9. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU
Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659
[TBL] [Abstract][Full Text] [Related]
10. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.
Lucci A; McCall LM; Beitsch PD; Whitworth PW; Reintgen DS; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Giuliano AE;
J Clin Oncol; 2007 Aug; 25(24):3657-63. PubMed ID: 17485711
[TBL] [Abstract][Full Text] [Related]
11. Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population.
Yi M; Kuerer HM; Mittendorf EA; Hwang RF; Caudle AS; Bedrosian I; Meric-Bernstam F; Wagner JL; Hunt KK
J Am Coll Surg; 2013 Jan; 216(1):105-13. PubMed ID: 23122536
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiology and end results (SEER) database.
Wang J; Mittendorf EA; Sahin AA; Yi M; Caudle A; Hunt KK; Wu Y
PLoS One; 2014; 9(2):e89778. PubMed ID: 24587029
[TBL] [Abstract][Full Text] [Related]
13. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
14. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A;
Lancet Oncol; 2018 Oct; 19(10):1385-1393. PubMed ID: 30196031
[TBL] [Abstract][Full Text] [Related]
15. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.
Shah-Khan M; Boughey JC
Cancer Control; 2012 Oct; 19(4):267-76. PubMed ID: 23037494
[TBL] [Abstract][Full Text] [Related]
16. Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study.
Peng Y; Liu M; Li X; Tong F; Cao Y; Liu P; Zhou B; Liu H; Cheng L; Guo J; Xie F; Yang H; Wang S; Wang C; Chen Y; Wang S
World J Surg Oncol; 2021 Apr; 19(1):128. PubMed ID: 33879180
[TBL] [Abstract][Full Text] [Related]
17. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
[TBL] [Abstract][Full Text] [Related]
18. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
[TBL] [Abstract][Full Text] [Related]
19. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
[TBL] [Abstract][Full Text] [Related]
20. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
